Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis

Back

ESC2025 Premium Access

Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis

Session: Treatment of transthyretin amyloidosis

Topic: Infiltrative Myocardial Disease

Speaker: Doctor T. Tsampras (Athens, GR)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Theodore Tsampras

National & Kapodistrian University of Athens Medical School, Athens (Greece)

1 presentation

0 follower

7 more presentations in this session

Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis

Speaker: Doctor V. Castiglione (Pisa, IT)

Optimizing treatment strategies for transthyretin amyloid cardiomyopathy: a comprehensive Bayesian network meta-analysis of disease-specific therapies

Speaker: Doctor M. Rahman (Flushing, US)

Diagnostic, therapeutic and prognostic implications of carpal tunnel syndrome and spinal stenosis in wild-type transthyretin cardiac amyloidosis.

Speaker: Doctor P. Debonnaire (Brugge, BE)

Which patients did recent trials in transthyretin amyloid cardiomyopathy select? - insights from a prospective patient registry

Speaker: Doctor L. Schmid (Vienna, AT)

Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM

Speaker: Doctor F. Cappelli (Florence, IT)

Access the full session

Treatment of transthyretin amyloidosis

Speakers: Doctor T. Tsampras, Doctor V. Castiglione, Doctor M. Rahman, Doctor P. Debonnaire, Doctor L. Schmid...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources